Form 8-K - Current report:
SEC Accession No. 0000950170-25-083444
Filing Date
2025-06-09
Accepted
2025-06-09 07:29:37
Documents
13
Period of Report
2025-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20250604.htm   iXBRL 8-K 53620
2 EX-10.1 engn-ex10_1.htm EX-10.1 889273
3 EX-10.2 engn-ex10_2.htm EX-10.2 33047
4 GRAPHIC img89482196_0.jpg GRAPHIC 884163
  Complete submission text file 0000950170-25-083444.txt   2476267

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20250604.xsd EX-101.SCH 45681
15 EXTRACTED XBRL INSTANCE DOCUMENT engn-20250604_htm.xml XML 6496
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 251032837
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)